| Filed On | Filing |
|---|---|
| 19 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) admini... |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 15 Jul 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 12 May 2026 | 8-K: Results of Operations and Financial Condition |
| 01 May 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities |
| 27 Apr 2026 | 8-K: Results of Operations and Financial Condition |
| 27 Apr 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 30 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 05 Feb 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
Loading...
